Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC

NCT03402464 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma

Interventions

DRUG: Icotinib combined dihydroaremisinin

Sponsor

Peking University Cancer Hospital & Institute

Collaborators

[object Object]